Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
European Cooperative Study of Primary Systemic Therapy in Women with Operable Breast Cancer >2 cm
ISRCTN96423607Phase 2Completed
- Sponsor
- Michelangelo Foundation
- Start
- Jun 2005
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
01
Overview
Phase 2, randomised, open-label trial of doxorubicin, paclitaxel, cyclophosphamide, methotrexate, fluorouracil and 2 more in breast cancer, sponsored by Michelangelo Foundation. Primary endpoint: Pathological complete response in breast. Started Jun 2005; status: completed.
02
Drugs
doxorubicinpaclitaxelcyclophosphamidemethotrexatefluorouracil
03
Conditions
breast cancer
Beyond the preview
Go deeper on ISRCTN96423607.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN96423607.